Abstract
BackgroundTNFi drug survival is one of the valid outcome measure in rheumatological diseases. Patients with psoriatic arthritis (PsA) usually have both joint/back pain diseases and skin disorders. Thus, efficacy of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
